Zhang L - Search Results

1

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma.

Zhang Y, Luo F, Ma YX, Liu QW, Yang YP, Fang WF, Huang Y, Zhou T, Li J, Pan HM, Yang L, Qin SK, Zhao HY, Zhang L. Zhang Y, et al. Among authors: zhang l. Oncologist. 2022 Jun 8;27(6):e453-e462. doi: 10.1093/oncolo/oyab076. Oncologist. 2022. PMID: 35445718 Free PMC article. Clinical Trial.

2

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.

Fang W, Huang Y, Gu W, Gan J, Wang W, Zhang S, Wang K, Zhan J, Yang Y, Huang Y, Zhao H, Zhang L. Fang W, et al. Among authors: zhang l, zhang s. Transl Lung Cancer Res. 2020 Aug;9(4):1258-1267. doi: 10.21037/tlcr-20-141. Transl Lung Cancer Res. 2020. PMID: 32953503 Free PMC article.

3

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.

4

Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer.

Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, Fang W, Chen X, Zhang Y, Zou B, Li Q, Wan Y, Chen H, Tang Y, Zhao J, Weng D, Xia L, Zhang L, Xia J. Liu H, et al. Among authors: zhang l, zhang y. Clin Transl Immunology. 2020 Oct 9;9(10):e1154. doi: 10.1002/cti2.1154. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33072320 Free PMC article.

5

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.

Zhou T, Zhang Z, Luo F, Zhao Y, Hou X, Liu T, Wang K, Zhao H, Huang Y, Zhang L. Zhou T, et al. Among authors: zhang l, zhang z. JAMA Netw Open. 2020 Oct 1;3(10):e2015748. doi: 10.1001/jamanetworkopen.2020.15748. JAMA Netw Open. 2020. PMID: 33074323 Free PMC article.

6

A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.

Ma Y, Fang W, Zhao H, Bathena SP, Tendolkar A, Sheng J, Zhang L. Ma Y, et al. Among authors: zhang l. Oncologist. 2021 Apr;26(4):e549-e566. doi: 10.1002/onco.13577. Epub 2020 Nov 11. Oncologist. 2021. PMID: 33105036 Free PMC article. Clinical Trial.

7

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.

Yang Y, Yang N, Wu L, Ouyang Q, Fang J, Li J, Liao W, Cai K, Huang J, Li J, Zhang Y, Wang X, Zhang H, Xu N, Zhao Q, Hu X, Li W, Zhong W, Zhong D, Cheng G, Ye S, Zhong M, Wang D, Liu H, Zheng J, Liu X, Xu H, Zhang L. Yang Y, et al. Among authors: zhang l, zhang h, zhang y. Chin Clin Oncol. 2020 Oct;9(5):68. doi: 10.21037/cco-20-160. Chin Clin Oncol. 2020. PMID: 33161724 Free article.

8

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer.

Guan S, Chen X, Xin S, Liu S, Yang Y, Fang W, Huang Y, Zhao H, Zhu X, Zhuang W, Wang F, Feng W, Zhang X, Huang M, Wang X, Zhang L. Guan S, et al. Among authors: zhang l, zhang x. Transl Oncol. 2021 Jan;14(1):100951. doi: 10.1016/j.tranon.2020.100951. Epub 2020 Nov 19. Transl Oncol. 2021. PMID: 33221684 Free PMC article.

9

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.

Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. Zhao S, et al. Among authors: zhang l, zhang z, zhang y. Front Oncol. 2020 Nov 10;10:587849. doi: 10.3389/fonc.2020.587849. eCollection 2020. Front Oncol. 2020. PMID: 33244458 Free PMC article.

10

Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).

Yang Y, Zhou H, Zhang L. Yang Y, et al. Among authors: zhang l. J Thorac Oncol. 2020 Dec;15(12):e191-e192. doi: 10.1016/j.jtho.2020.09.028. J Thorac Oncol. 2020. PMID: 33246599 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124,998 results

Search Page